The Psychedelics Newsletter, Issue 122

ELE-101 – BECKLEY PSYTECH’S IV FORMULATION OF PSILOCIN

At the end of last year,?Beckley Psytech?announced the acquisition of life science company?Eleusis.

The procurement was largely based on the potential of ELE-101,?Eleusis’?IV formulation of psilocin which the team believes may have?a shorter treatment duration and less variability compared with oral forms of psilocybin.

Members of?Eleusis’ management team were subsequently integrated into the organisation’s C-suite, with Senior Vice President Rob Conley transitioning into?Beckley Psytech’s Chief Scientific Officer.

Rob Conley brings to the table a wealth of drug development experience, having previously served as Chief Scientific Officer for Neuroscience at Eli Lilly. To discuss the potential of ELE-101 to treat major depressive disorder cost-effectively, PSYCH spoke with?Beckley Psytech’s new CSO.

READ MORE

UK ANNOUNCES NEW DRUG AUTHORISATION MODEL

The update may make psychedelic medicines accessible to patients in the UK before they are available in the EU.

READ MORE

NEUROIMAGING STUDY CONDUCTED WITH PATIENTS ON DMT

It showed increased connectivity across the brain, with more communication between different areas.

READ MORE

BUSINESS AND INVESTMENT

• Field Trip to?close five clinics.?By downsizing, the company hopes to preserve capital and reduce expenditure.
• Clairvoyant doses first European patient in?Phase II psilocybin trial.?The study hope to find an effective treatment for alcohol use disorder.
• Wesana sells SANA-13 assets to?Lucy Scientific Discovery.?The protocol combines psilocybin and CBD.
• Psychedelic medicines will need billing and?coding systems.?Therapies will need to be integrated into the medical framework.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023. Early Bird tickets on sale for ￡299 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

• Mystical drug experiences?improve mental health.?The insights acquired may reduce anxiety and depression.
• Threats to validity of?psychedelic research.?Scientists warn of unsound conclusions on safety and efficacy.

REGULATION AND LEGISLATION

• Majority of Americans back?legalising psychedelic therapies.?60% support the regulation of psychedelic medicine.
• California senators approve bill?legalising psychedelic therapy.?The legislation was amended and refiled.
• Mexico could?regulate psychedelic medicines.?Renewed optimism follows the verdict of an ayahuasca trial.
• Nevada lawmakers file bill to?legalise psilocybin and MDMA.?The law hopes to enable further psychedelic research.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to engage?with an?audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

• The impact of the rising?cost of living.?Greater inequality is expected to exacerbate the mental health crisis.
• Art and technology can?improve mental health.?The combination may better?treat mental health conditions.